1. Home
  2. LFMD vs ACIU Comparison

LFMD vs ACIU Comparison

Compare LFMD & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LifeMD Inc.

LFMD

LifeMD Inc.

N/A

Current Price

$2.20

Market Cap

218.1M

Sector

Health Care

ML Signal

N/A

Logo AC Immune SA

ACIU

AC Immune SA

N/A

Current Price

$2.12

Market Cap

229.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LFMD
ACIU
Founded
1994
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
218.1M
229.7M
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
LFMD
ACIU
Price
$2.20
$2.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
4
Target Price
$8.13
★ $8.58
AVG Volume (30 Days)
★ 874.6K
195.8K
Earning Date
11-12-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 141.67
N/A
EPS
N/A
★ N/A
Revenue
★ $12,468,578.00
N/A
Revenue This Year
$5.37
$422.39
Revenue Next Year
$17.75
$377.85
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 49.79
N/A
52 Week Low
$1.60
$2.02
52 Week High
$5.38
$3.90

Technical Indicators

Market Signals
Indicator
LFMD
ACIU
Relative Strength Index (RSI) 47.88 41.11
Support Level $2.06 $2.09
Resistance Level $2.49 $2.57
Average True Range (ATR) 0.22 0.19
MACD -0.01 -0.00
Stochastic Oscillator 66.85 18.69

Price Performance

Historical Comparison
LFMD
ACIU

About LFMD LifeMD Inc.

LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: